title: Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
abstract: OBJECTIVE
  Axiron (testosterone topical solution 2%) is an approved topical testosterone replacement therapy applied to the axilla. The axilla is a novel application site for testosterone replacement therapy, with differences in skin structure and exposure that could impact the type and/or severity of skin reactions observed with testosterone topical solution 2%. We therefore present a detailed description of data from a pivotal clinical trial regarding the incidence, time of onset, duration, and severity of patient-reported skin reactions as well as visual assessments made by investigators and rated using Draize scoring. *Axiron is a trademark of Eli Lilly and Company, Indianapolis, IN, USA.
  
  
  METHODS
  Data were analyzed from a multinational, open-label, clinical study in which a 2% testosterone topical solution was applied to the axilla in hypogonadal men. The primary study was for 120 days (N = 155) with a 60-day extension that evaluated skin safety (N = 71). At each visit investigators asked patients about adverse skin reactions (including those occurring between study visits); visually assessed the application site; and graded observed instances of erythema or edema using Draize scoring (rated from 0 to 4).
  
  
  RESULTS
  Application-site irritation following study drug application was the most commonly reported event (n = 12 patients) and was generally mild (n = 11; moderate, n = 1) in severity. Application-site irritation did not increase in severity over time and led to only one discontinuation. Erythema was the second most common patient-reported skin reaction (n = 10 patients) and was also generally mild (n = 9; moderate, n = 1). Draize scoring rated all directly observed cases of erythema as grade 1 (very slight, 6 patients) or grade 2 (well-defined, two patients), and identified two instances of erythema not reported by patients. Erythema was typically transient, and in most cases resolved without interruption of therapy. Three cases of edema were reported by patients, and two of these were also identified by visual inspection; all cases of edema occurred in conjunction with erythema. Two cases of acne (facial, shoulders) and one of folliculitis (scalp) were also reported.
  
  
  CONCLUSIONS
  Skin reactions were observed in a minority of patients, were mild or at most moderate in severity, and seldom led to discontinuation.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA. muram_david@lilly.com
authors.forename: David
authors.initials: D
authors.lastname: Muram
authors.forename: Thomas
authors.initials: T
authors.lastname: Melby
authors.forename: Erin
authors.initials: E
authors.lastname: Alles Kingshill
mesh_terms: D000152:Acne Vulgaris / Q000139:chemically induced; D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D001365:Axilla; D004305:Dose-Response Relationship, Drug; D004890:Erythema / Q000139:chemically induced; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000187:drug effects*; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors; D055815:Young Adult
chemical_list: D013739:Testosterone